Linked e-resources
Details
Table of Contents
Intro; Foreword; Contents; Contributors; Chapter 1: Psychopharmacology for Neurologists; Clinical Vignette; Discussion; Scope of this Book; References; Chapter 2: General Principles of Psychopharmacology; Pharmacokinetics Vs. Pharmacodynamics; Pharmacokinetics; Pharmacodynamics; Drug Interactions; FDA Drug Approval; Off-Label Use; DEA Schedules of Drugs; Common Side Effects of Psychotropic Drugs and How to Manage Them; Neurotransmitter Systems; Specific Side Effects of Newer Psychotropic Drugs; Weight Gain; Sexual Dysfunction; Movement Disorders; Cardiovascular; Weight Loss; Hyponatremia
Cognitive ImpairmentSerum Glucose Alterations; Gastrointestinal Issues; Rash; What Is a Black Box Warning and Which Psychotropes Have One?; Drug Withdrawal/Discontinuation; Pregnant and Nursing Women: Special Considerations; Hepatic/Renal Insufficiency: Impact on Dosing; Renal Insufficiency; Hepatic Insufficiency; Laboratory Monitoring; Lithium Serum Levels; WBC for Clozapine and Carbamazepine; TCAs for Depression; Antipsychotics; Conclusion; References; Chapter 3: Special Considerations for the Elderly; Basic Principles of Geriatric Psycho-pharmacotherapy; Document Target Symptoms
Case StudyEnsure Close Collaboration Among Various Prescribers; Start One Medication at a Time; Start Low and Go Slow, But Go; Hepatic and Renal Considerations; Knowledge of Available Formulations; Knowledge of Drug-Drug Interactions; Assess Role of Gender, Lifestyle, Racial/Ethnic Differences in Drug Metabolism and Tolerance; Monitoring for Drug Response, Toxicity, and Interactions; Avoid Introducing a Drug to Treat the Side Effects of Another Drug; Case Study; Reducing Medication Burden; Periodic Drug Tapering and Discontinuation if Symptoms Are Well-Controlled; Patient and Family Education
Medication Cost/ReimbursementConclusion; References; Chapter 4: Antidepressants; Identifying Depression; Case Vignette: Part 1; Depression Screening; Subsyndromal Depression and Persistent Depressive Disorder; Case Vignette: Part 2; Subsyndromal Depression; Persistent Depressive Disorder (Dysthymia); Major Depressive Disorder; Case Vignette: Part 3; Diagnosing Major Depressive Disorder; Assessing Depression Severity; Completing the Assessment; Clinical Vignette: Part 3; Discussion; Prescribing an Antidepressant; Case Vignette: Part 4; Selecting an Antidepressant
Antidepressants for NeurologistsEvaluating and Adjusting Treatment; Case Vignette: Part 5; Evaluating Treatment Response; Continuing or Increasing the Antidepressant; Changing Antidepressants, if Not Effective; Goals and Duration of Treatment; Case Vignette: Part 6; Treat Residual Symptoms Fully; Duration of Treatment; Psychotherapy; Adverse Effects; Case Vignette: Part 7; Common Adverse Effects; Serious Adverse Effects; Other Adverse Effects; Discontinuation Syndrome; Neurological Illnesses; Epilepsy; Parkinson's Disease; Stroke; Multiple Sclerosis; Scales for Evaluating Treatment Response
Cognitive ImpairmentSerum Glucose Alterations; Gastrointestinal Issues; Rash; What Is a Black Box Warning and Which Psychotropes Have One?; Drug Withdrawal/Discontinuation; Pregnant and Nursing Women: Special Considerations; Hepatic/Renal Insufficiency: Impact on Dosing; Renal Insufficiency; Hepatic Insufficiency; Laboratory Monitoring; Lithium Serum Levels; WBC for Clozapine and Carbamazepine; TCAs for Depression; Antipsychotics; Conclusion; References; Chapter 3: Special Considerations for the Elderly; Basic Principles of Geriatric Psycho-pharmacotherapy; Document Target Symptoms
Case StudyEnsure Close Collaboration Among Various Prescribers; Start One Medication at a Time; Start Low and Go Slow, But Go; Hepatic and Renal Considerations; Knowledge of Available Formulations; Knowledge of Drug-Drug Interactions; Assess Role of Gender, Lifestyle, Racial/Ethnic Differences in Drug Metabolism and Tolerance; Monitoring for Drug Response, Toxicity, and Interactions; Avoid Introducing a Drug to Treat the Side Effects of Another Drug; Case Study; Reducing Medication Burden; Periodic Drug Tapering and Discontinuation if Symptoms Are Well-Controlled; Patient and Family Education
Medication Cost/ReimbursementConclusion; References; Chapter 4: Antidepressants; Identifying Depression; Case Vignette: Part 1; Depression Screening; Subsyndromal Depression and Persistent Depressive Disorder; Case Vignette: Part 2; Subsyndromal Depression; Persistent Depressive Disorder (Dysthymia); Major Depressive Disorder; Case Vignette: Part 3; Diagnosing Major Depressive Disorder; Assessing Depression Severity; Completing the Assessment; Clinical Vignette: Part 3; Discussion; Prescribing an Antidepressant; Case Vignette: Part 4; Selecting an Antidepressant
Antidepressants for NeurologistsEvaluating and Adjusting Treatment; Case Vignette: Part 5; Evaluating Treatment Response; Continuing or Increasing the Antidepressant; Changing Antidepressants, if Not Effective; Goals and Duration of Treatment; Case Vignette: Part 6; Treat Residual Symptoms Fully; Duration of Treatment; Psychotherapy; Adverse Effects; Case Vignette: Part 7; Common Adverse Effects; Serious Adverse Effects; Other Adverse Effects; Discontinuation Syndrome; Neurological Illnesses; Epilepsy; Parkinson's Disease; Stroke; Multiple Sclerosis; Scales for Evaluating Treatment Response